Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle

Breneman, Debra; Fleischer, Alan B.; Abramovits, William; Zeichner, Joshua; Gold, Michael H.; Kirsner, Robert S.; Shull, Toni; Crowe, Andrew; Jaracz, Eileen; Hanifin, Jon M.

doi:10.1016/j.jaad.2008.02.008

Cited by 98 publications

(78 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The severity of relapses was similar for both groups (p = .140) as was the incidence of cutaneous adverse events (tacrolimus ointment = 8.0%; vehicle = 8.5%). The most common adverse events were application-site burning and pruritus (D. Breneman, 2008). CONCLUSIONS Long-term treatment with tacrolimus ointment in patients with clear or almost clear AD results in significantly more disease-free days and safely and effectively reduces the risk for disease relapse.…”

Section: The Importance Of Sun Protection In Organ Transplant Recipientsmentioning

confidence: 98%

See 1 more Smart Citation

Creating a Pathway to Best Clinical Practice for Cutaneous T-Cell Lymphoma

Booher¹

2009

Journal of the Dermatology Nurses' Association

View full text Add to dashboard Cite

Section: The Importance Of Sun Protection In Organ Transplant Recipientsmentioning

confidence: 98%

“…The safety and efficacy of tacrolimus therapy for recurrence prevention were evaluated (D. Breneman, 2008). RESULTS A total of 197 of 288 patients with clear or almost clear disease were eligible and entered the maintenance phase of this study.…”

Section: The Importance Of Sun Protection In Organ Transplant Recipientsmentioning

confidence: 99%

Creating a Pathway to Best Clinical Practice for Cutaneous T-Cell Lymphoma

Booher¹

2009

Journal of the Dermatology Nurses' Association

View full text Add to dashboard Cite

“…Orta ya da yüksek güçteki steroid ile başlayıp iyileşen alana aralıklı olarak topikal takrolimus pomad uygulamanın bir sonraki ataktan ve tekrar TKS gerekliliğinden korumak için etkili bir yol olduğu gösterilmiştir 92 .…”

Section: Topikal Kortikosteroidler Ile Kombine Kullanımıunclassified

The Turkish guideline for the diagnosis and management of atopic dermatitis-2018

Ertam¹,

Küçük²,

Alper³

et al. 2018

TURKDERM

View full text Add to dashboard Cite

show abstract

“…All the uncertainties identified by this PSP have been added to the UK DUETs 350 to provide reference for funding bodies and researchers. The challenge now is to utilise existing and new partnerships, such as those developed during this process, to undertake high-quality, pragmatic trials that reflect the priorities of people who live with or treat eczema on a daily basis.…”

Section: Uncertainty Suggested Research Question(s)mentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle

Cited by 98 publications

References 26 publications

Creating a Pathway to Best Clinical Practice for Cutaneous T-Cell Lymphoma

Creating a Pathway to Best Clinical Practice for Cutaneous T-Cell Lymphoma

The Turkish guideline for the diagnosis and management of atopic dermatitis-2018

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Contact Info

Product

Resources

About